Abstract:Background: Polymer-free drug-eluting stents (DES) without permanent-polymer coating may be associated with rapid vessel healing, providing a rationale to reduce dual-antiplatelet therapy (DAPT). The aim of the current study was to compare vessel healing of a polymer-free sirolimus-eluting stent (PF-SES), its bare metal stent (BMS) analogue to a permanent polymer-based sirolimus-eluting stent (SES) with proven effectiveness in porcine coronary arteries. Material and methods: An ultrathin-strut cobalt–chromium PF-SES, its BMS analogue and an SES with a permanent polymer were used to study vessel healing and their antistenotic potential. Stents were implanted in porcine coronary arteries for histopathologic analysis at 7, 28 and 180 days. In an additional in vitro study, the thrombogenicity of PF-SES was compared with a fluoropolymer-coated everolimus-eluting stent (EES) which demonstrated low stent thrombosis rates in numerous studies. Results: In the animal study, neointimal growth and injury scores were minimal and inflammation scores were low in the neointima and adventitia in all study groups. After 28 days, neointimal area was lowest in PF-SES when compared with SES and BMS (1.48 ± 0.55 mm2 versus 2.43 ± 0.69 mm2 versus 1.90 ± 0.85 mm2, respectively, p 0.05). At 180 days, neointimal area and thickness were most pronounced in SES ( p < 0.05) and comparable with BMS implantations, which were characterized by nearly completed vessel healing. PF-SES and BMS had complete endothelialization, absence of fibrin and sustained low inflammatory reaction when compared with the permanent polymer-based SES (inflammation score: PF-SES 0.41 ± 0.74 versus SES 2.52 ± 1.72 versus BMS 0.30 ± 0.65, respectively, p 0.05). In the in vitro thrombogenicity study, the PF-SES confirmed comparable antithrombogenic properties with regard to the parameters fibrin and platelet binding, and platelet aggregation when compared with the EES. Conclusions: As compared with BMS, the ultrathin-strut cobalt–chromium PF-SES showed similar endothelialization at 28 days and comparable healing characteristics at 180 days efficacious inhibition of neointimal proliferation in porcine coronary arteries with low inflammation responses and a BMS-like endothelialization at 180 days. In addition, in an in vitro model, the PF-SES also confirmed low thrombogenicity as compared with the EES.

Efficacy and Safety of a Novel Nano-Porous Polymer-Free Sirolimus-Eluting Stent in Pigs.

Evaluation of a novel polymer-free sirolimus-eluting stent in a porcine model

Long-Term Effects of Novel Biodegradable, Polymer-Coated, Sirolimus-Eluting Stents on Neointimal Formation in A Porcine Coronary Model

A novel biodegradable polymer coated,sirolimus-eluting stent: evaluation in a porcine coronary model

A novel biodegradable polymer-coated cobalt-chromium alloy sirolimus-eluting stent：evaluation in a porcine model

Polymer-free Dual Drug-Eluting Stents Evaluated in a Porcine Model

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Accelerated Endothelialization with a Polymer-Free Sirolimus-Eluting Antibody-Coated Stent.

Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries

Effect of the implantation of the new sirolimus-eluting stent with modified polymer on the neointimal repairment:an experimental study in swine

The Experimental Study in a Novel Targeting Sirolimus-Eluting Stents With Biodegradable Polymer for Preventing In-Stent Stenosis in Porcine Model

Safety and Efficacy of Cobalt Chromium Alloy Based Sirolimus-Eluting Stent with Bioabsorbable Polymer in Porcine Model.

A Biodegradable-Polymer-plga-coated,sirolimus-eluting Cobalt-chromium Alloy Stent:Safety and Efficacy Evaluation in a Porcine Model

High nitrogen stainless steel drug-eluting stent - Assessment of pharmacokinetics and preclinical safety in vivo

Preclinical evaluation of the functionality of a polymer-coated sirolimuseluting stent in pigs

Assessment of an Asymmetrical Coating Stent with Sirolimus Released from Ablumial Matrix in Porcine Model

AS-30: the Preclinical Assessment of a Novel Biodegradable Rapid Prohealing Polymer with Sirolimus -Eluting Coating Stent in Porcine Model

AS-023: Efficacy and Safety of a Novel Non-Symmetrical, Biodegradable Polymer-Coated Sirolimus-Eluting Stent in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine

Nine-month Angiographic and Two-Year Clinical Follow-Up of Polymer-Free Sirolimus-Eluting Stent Versus Durable-Polymer Sirolimus-Eluting Stent for Coronary Artery Disease: the Nano Randomized Trial.

Evaluation of a Novel Paclitaxel-Eluting Stent with a Bioabsorbable Polymeric Surface Coating in the Porcine Artery Injury Model